Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Caitlin E. Cox

March 30, 2025

Presentation ACC 2025

Dapagliflozin after Transcatheter Aortic Valve Implantation

Presenter: Sergio Raposeiras-Roubin

March 29, 2025

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Caitlin E. Cox

April 15, 2024

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

L.A. McKeown

April 06, 2024

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

News Conference News ACC 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

Michael O'Riordan

April 06, 2024

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

News Conference News ACC 2023

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

L.A. McKeown

March 14, 2023

News Conference News ACC 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

Todd Neale

March 09, 2023

News Conference News ACC 2023

STELLAR, ‘Impressive’ Results With Novel Drug Sotatercept in PAH

Shelley Wood

March 06, 2023

News Conference News ACC 2023

BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF

L.A. McKeown

March 06, 2023

Presentation ACC 2023

Impact of Heart Failure Management Using Thoracic Fluid Monitoring From A Novel Wearable Sensor: Results of the Benefits of Microcor (μCor™) in Ambulatory Heart Failure (BMAD) Trial

Presenter: John P. Boehmer

March 05, 2023

News Conference News ACC 2022

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

L.A. McKeown

April 08, 2022

News Conference News ACC 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

Todd Neale

April 08, 2022

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

Presentation ACC 2022

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Presenter: Florian Rader

April 04, 2022

Presentation ACC 2022

The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF

Presenter: Michael Felker

April 04, 2022

Presentation ACC 2022

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

Presenter: Tariq Ahmad

April 04, 2022

News Conference News ACC 2022

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

L.A. McKeown

April 03, 2022

Advertisement

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Dapagliflozin after Transcatheter Aortic Valve Implantation

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

STELLAR, ‘Impressive’ Results With Novel Drug Sotatercept in PAH

BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF

Impact of Heart Failure Management Using Thoracic Fluid Monitoring From A Novel Wearable Sensor: Results of the Benefits of Microcor (μCor™) in Ambulatory Heart Failure (BMAD) Trial

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content